The director of the Serum Institute of India, Adar Poonawalla, remains optimistic about the Oxford covid vaccine, as the coronavirus pandemic claimed close to 9 lakh of lives worldwide. Considered a pioneer in the global race to offer an effective vaccine to combat Covid-19, the University of Oxford’s AstraZeneca vaccine is now in phase III clinical trials in Great Britain, Brazil, South Africa and India.
“Proud and excited for the next few months and looking forward to the vaccine,” Poonawalla tweeted.
In her tweet, Poonawalla shared a photograph standing next to the legendary Edward Jenner statue at Oxford University, along with Professor Adrian Hill. In India, the Oxford covid vaccine is undergoing advanced trials.
Recently, Serum Institute of India CEO Adar Poonawalla was named among Fortune’s “Emerging Leaders” from around the world on its annual list of influencers under 40 years of age.
The Serum Institute is the world’s largest manufacturer of vaccines by volume. And it has signed an agreement to manufacture the possible vaccine developed by the Jenner Institute at the University of Oxford in collaboration with the British-Swedish pharmaceutical company AstraZeneca.
Professor Hill is director of the Jenner Institute, which focuses on the design and development of vaccines for infectious diseases prevalent in developing countries.
Serum Institute of India has partnered with Gavi, The Vaccine Alliance, and the Bill & Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries. .
The Serum Institute of India has also signed a supply and a license with the US vaccine manufacturer Novavax Inc for the development and commercialization of its COVID-19 candidate vaccine.
The Indian vaccine manufacturer will have exclusive rights to the vaccine in India during the term of the agreement and non-exclusive rights during the “Pandemic Period” in all countries other than those designated by the World Bank as upper or upper middle income countries. . .
.
.
